Oric Pharmaceuticals (NASDAQ:ORIC) Given “Buy” Rating at HC Wainwright

Oric Pharmaceuticals (NASDAQ:ORIC)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $25.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 233.33% from the stock’s current price.

Several other research analysts have also issued reports on the company. Wedbush cut their price target on Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, April 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Tuesday, April 21st. Wall Street Zen lowered Oric Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. Oppenheimer reiterated an “outperform” rating and issued a $15.00 price target on shares of Oric Pharmaceuticals in a report on Tuesday, February 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Oric Pharmaceuticals in a report on Friday, May 22nd. Twelve investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $19.36.

Oric Pharmaceuticals Stock Performance

Shares of ORIC stock opened at $7.50 on Monday. The stock has a market cap of $776.40 million, a price-to-earnings ratio of -5.21 and a beta of 1.04. The stock has a 50-day moving average of $9.38 and a 200-day moving average of $10.29. Oric Pharmaceuticals has a 1-year low of $7.23 and a 1-year high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Monday, May 4th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.03). Sell-side analysts forecast that Oric Pharmaceuticals will post -1.43 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Royce & Associates LP lifted its holdings in Oric Pharmaceuticals by 521.2% during the third quarter. Royce & Associates LP now owns 1,458,483 shares of the company’s stock worth $17,502,000 after acquiring an additional 1,223,709 shares during the period. UBS Group AG lifted its holdings in Oric Pharmaceuticals by 116.6% during the fourth quarter. UBS Group AG now owns 734,858 shares of the company’s stock worth $6,011,000 after acquiring an additional 395,622 shares during the period. Rafferty Asset Management LLC lifted its holdings in Oric Pharmaceuticals by 100.7% during the third quarter. Rafferty Asset Management LLC now owns 85,592 shares of the company’s stock worth $1,027,000 after acquiring an additional 42,948 shares during the period. Blue Owl Capital Holdings LP bought a new stake in Oric Pharmaceuticals during the fourth quarter worth $4,213,000. Finally, Legato Capital Management LLC bought a new stake in Oric Pharmaceuticals during the third quarter worth $281,000. Institutional investors own 95.05% of the company’s stock.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.